CoChat

Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Abstract

Background Determination of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status is standard for predicting prognosis and determining treatment options for patients with breast cancer. In 2010, the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) issued guidelines that tumors with ≥1% positively staining cells should be considered ER positive. Here, we determined how this cutoff relates to molecular subtype. Methods Clinicopathological characteristics were compared between ER-negative, ER-positive, and low-ER-staining (1-10%) tumors using chi-square analysis with P Results Low-ER-staining tumors were clinicopathologically more similar to ER-negative than to ER-positive tumors; 88% of low-staining tumors were basal like or HER2 enriched. Only those tumors expressing 10% ER-positive cells were classified as luminal A subtype. Conclusions Under ASCO/CAP guidelines, tumors with 1-10% ER staining would be classified as ER positive, yet most are basal like or HER2 enriched and have pathological features similar to ER-negative tumors. Clinical trials seeking to treat tumors of ER-negative basal-like and/or HER2-enriched subtypes should thus not preclude enrollment based solely on results of ER immunohistochemistry. As ER status is a critical element in the choice of treatments for patients with breast cancer, it is imperative that the most effective method for classifying tumors be devel…

Overview

Integrity signals

Registry

Crossref · 10.1245/s10434-012-2588-8

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Cited by

See all 149

Metadata

Authors
Deyarmin, B., Kane, J. L., Valente, A. L., van Laar, R., Gallagher, C., Shriver, C. D., & Ellsworth, R. E.
Affiliations
  • Windber Research Institute (US)
  • Walter Reed National Military Medical Center (US)
  • Henry M. Jackson Foundation (US)
Corresponding author
Ellsworth, Rachel E.
Venue
Annals of Surgical Oncology
Published
2012-08-09
Volume
20
Issue
1
Pages
87-93
ISSN
  • 1068-9265 (ISSN-L)
  • 1534-4681
OpenAlex
W2037559407
Cited by
149
References
30
Citations by year
2026: 3 · 2025: 6 · 2024: 11 · 2023: 16 · 2022: 12 · 2021: 16 · 2020: 10 · 2019: 15 · 2018: 11 · 2017: 3 · 2016: 16 · 2015: 12 · 2014: 12 · 2013: 6
FWCI
3.18
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Annals of Surgical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
breast cancer, estrogen receptor status, ASCO/CAP guidelines, molecular subtypes, basal-like breast cancer, HER2-enriched breast cancer, luminal A, gene expression profiling, clinicopathological features
MeSH terms
Adult, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Immunohistochemistry, Middle Aged, Receptors, Estrogen, RNA, Gene Expression, Chi-Square Distribution, Treatment Outcome, Practice Guidelines as Topic, Erb-b2 Receptor Tyrosine Kinases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype. https://app.cochat.ai/papers/10.1245/s10434-012-2588-8
The paper
Deyarmin, B., Kane, J. L., Valente, A. L., van Laar, R., Gallagher, C., Shriver, C. D., & Ellsworth, R. E. (2013). Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-012-2588-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.